Galmed Pharmaceuticals Ltd. (GLMD) Fair Value 2026

GLMD · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

DANGER (100/100)

Quick Summary — As of 2026-08-28, Galmed Pharmaceuticals Ltd. (GLMD) trades at $4.17. QOC: 2.5/10. Value Trap Risk: 100/100 (DANGER). 0/13 models active.

Key Facts

Ticker
GLMD
Price
$4.17
Quality Score
2.5/10
Value Trap Risk
100/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 100 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give GLMD?

0 Intrinsic Value Models vs. Current Price ($4.17)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Galmed Pharmaceuticals Ltd. (GLMD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Galmed Pharmaceuticals Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About GLMD?

0 of 13 models are currently active for GLMD. See which stocks rank higher →

How Does GLMD Rank in Biotechnology?

Among 625 Biotechnology stocks, GLMD ranks #607 by Quality of Company score. CirclFi's QOC score of 2.5/10 evaluates 32 fundamental signals. A score of 2.5 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Galmed Pharmaceuticals Ltd.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including gene therapy and cell therapy innovation — shape both the opportunity set and risk profile.

Is GLMD a Value Trap?

CirclFi's Value Trap algorithm assigns GLMD a score of 100/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Galmed Pharmaceuticals Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Galmed Pharmaceuticals Ltd. earns a quality score of 2.5/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. However, our Value Trap algorithm flags elevated risk — suggesting that apparent cheapness may mask deteriorating fundamentals.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GLMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Galmed Pharmaceuticals Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

XTLBXTL Biopharmaceuticals Ltd.QOC 2.5CANFCan-Fite BioPharma Ltd.QOC 2.5OKYOOKYO Pharma LimitedQOC 2.5TLSATiziana Life Sciences LtdQOC 2.5SLGLSol-Gel Technologies Ltd.QOC 2.6EPRXEupraxia Pharmaceuticals Inc.QOC 2.4STTKShattuck Labs, Inc.QOC 6.1IMNMImmunome, Inc.QOC 5.1PEPGPepGen Inc.QOC 4.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: XTLB · CANF · OKYO · TLSA · SLGL · EPRX · STTK · IMNM · PEPG · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to GLMD?

7 companies across all industries closest to GLMD’s Quality of Company score of 2.5/10.

CXCEMEX, S.A.B. de C.V.QOC 2.5XNETXunlei LimitedQOC 2.5JWELJowell Global Ltd.QOC 2.5HKPDCellyan Biotechnology Co., LtdQOC 2.5HIMXHimax Technologies, Inc.QOC 2.5TATTTAT Technologies Ltd.QOC 2.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CX · XNET · JWEL · HKPD · HIMX · TATT · NVDA

Where Does GLMD Sit in CirclFi's Biotechnology Rankings?

GLMD is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Galmed Pharmaceuticals Ltd.’s Valuation?

What is Galmed Pharmaceuticals Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Galmed Pharmaceuticals Ltd. (GLMD). The Quality of Company score is 2.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GLMD overvalued or undervalued right now?

At $4.17, 0 of 0 active models suggest GLMD may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Galmed Pharmaceuticals Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 2.5 mean for GLMD?

Galmed Pharmaceuticals Ltd.'s QOC of 2.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on GLMD?

CirclFi analyzes GLMD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is GLMD a value trap in 2026?

Galmed Pharmaceuticals Ltd.'s Value Trap score is 100/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Galmed Pharmaceuticals Ltd. (GLMD) a Quality of Company score of 2.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/GLMD/ · Methodology
Primary sources for this GLMD valuation
  • Financial statements: Galmed Pharmaceuticals Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001595353) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GLMD as of ; valuations recomputed .